For localized prostate cancer, multimodal artificial intelligence models have revealed a more accurate way to assess prostate cancer risk. By combining advanced artificial intelligence with digital pathology images and clinical data, researchers developed a way to approach risk classification that outperforms traditional methods. These findings were published in JCO Precision Oncology. The research found that...
One of the greatest challenges in cancer immunotherapy is finding the rare immune cells, called tumor-reactive T cells, whose job it is to recognize and eliminate tumor cells.
